Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 11 de 11
1.
BMJ Open ; 13(9): e065692, 2023 09 18.
Article En | MEDLINE | ID: mdl-37723106

OBJECTIVE: To estimate the 'cost of illness' arising from chronic wounds in Singapore. DESIGN: Incidence-based cost of illness study using evidence from a range of sources. SETTING: Singapore health services. PARTICIPANTS: We consider 3.49 million Singapore citizens and permanent residents. There are 16 752 new individuals with a chronic wound in 2017, with 598 venous ulcers, 2206 arterial insufficiency ulcers, 6680 diabetic ulcers and 7268 pressure injuries.Primary outcome measures expressed in monetary terms are the value of all hospital bed days lost for the population; monetary value of quality-adjusted life years (QALYs) lost in the population; costs of all outpatient visits; and costs of all poly clinic, use of Community Health Assist Scheme (CHAS) and emergency departments (EDs) visits. Intermediate outcomes that inform the primary outcomes are also estimated. RESULTS: Total annual cost of illness was $350 million (range $72-$1779 million). With 168 503 acute bed days taken up annually (range 141 966-196 032) that incurred costs of $139 million (range 117-161 million). Total costs to health services were $184 million (range $120-$1179 million). Total annual costs of lost health outcomes were 2077 QALYs (range -2657 to 29 029) valued at $166 million (range -212 to 2399 million). CONCLUSIONS: The costs of chronic wounds are large to Singapore. Costs can be reduced by making positive investments for comprehensive wound prevention and treatment programmes.


Asian , Cost of Illness , Ulcer , Humans , Ambulatory Care Facilities , Asian/ethnology , Asian/statistics & numerical data , Emergency Service, Hospital , Emigrants and Immigrants , Ulcer/economics , Ulcer/epidemiology , Ulcer/ethnology , Ulcer/therapy , Chronic Disease/economics , Chronic Disease/epidemiology , Chronic Disease/ethnology , Chronic Disease/therapy , Singapore/epidemiology
2.
J Dairy Sci ; 102(1): 715-730, 2019 Jan.
Article En | MEDLINE | ID: mdl-30415843

A farm-level stochastic simulation model was modified to estimate the cost per case of 3 foot disorders (digital dermatitis, sole ulcer, and white line disease) by parity group and incidence timing. Disorder expenditures considered within the model included therapeutics, outside labor, and on-farm labor. Disorder losses considered within the model included discarded milk, reduced milk production, extended days open, an increased risk of culling, an increased risk of death (natural or euthanized), and disease recurrence. All estimates of expenditures and losses were defined using data from previously published research in stochastic distributions. Stochastic simulation was used to account for variation within the farm model; 1,000 iterations were run. Sensitivity of foot disorder costs to selected market prices (milk price, feed price, replacement heifer price, and slaughter price) and herd-specific performance variables (pregnancy rate) were analyzed. Using our model assumptions, the cost per disorder case over all combinations of parity group and incidence timing, regardless of incidence likelihood, was lowest for digital dermatitis ($64 ± 24; mean ± standard deviation), followed by white line disease ($152 ± 26) and sole ulcer ($178 ± 29). Disorder costs were greater in multiparous versus primiparous cows and were always highest at the beginning of lactation. The greatest contributing cost categories were decreased milk production, an increased risk of culling, and disease recurrence. The contribution of cost categories to the total cost of disorder varied by disorder type, parity group, and incidence timing. For all disorders, the cost per case increased as milk price or replacement heifer price increased and decreased as feed price, pregnancy rate, or slaughter price increased. Understanding how foot disorder costs change according to cow-specific conditions (i.e., disorder type, parity group, and days in milk at incidence) and herd-specific conditions (i.e., market prices and performance variables) can help improve on-farm decisions about treatment and prevention of foot disorders.


Cattle Diseases/economics , Foot Diseases/veterinary , Hoof and Claw , Parity , Animals , Cattle , Cattle Diseases/epidemiology , Cattle Diseases/physiopathology , Costs and Cost Analysis , Dairying/economics , Digital Dermatitis/economics , Digital Dermatitis/epidemiology , Farms , Female , Foot Diseases/economics , Foot Diseases/epidemiology , Lactation/physiology , Milk , Pregnancy , Stochastic Processes , Ulcer/economics , Ulcer/veterinary
3.
Infect Dis Poverty ; 7(1): 12, 2018 Feb 14.
Article En | MEDLINE | ID: mdl-29444705

BACKGROUND: The present health economic evaluation in Afghanistan aims to support public health decision makers and health care managers to allocate resources efficiently to appropriate treatments for cutaneous leishmaniasis (CL) elicited by Leishmania tropica or Leishmania major. METHODS: A decision tree was used to analyse the cost and the effectiveness of two wound care regimens versus intra-lesional antimony in CL patients in Afghanistan. Costs were collected from a societal perspective. Effectiveness was measured in wound free days. The incremental cost-effectiveness ratio (ICER) and incremental net monetary benefit (NMB) were calculated. The model was parameterized with baseline parameters, sensitivity ranges, and parameter distributions. Finally, the model was simulated and results were evaluated with deterministic and probability sensitivity analyses. Final outcomes were the efficiency of the regimens and a budget impact analysis in the context of Afghanistan. RESULTS: Average costs per patients were US$ 11 (SE = 0.016) (Group I: Intra-dermal Sodium Stibogluconate [IL SSG]), US$ 16 (SE = 7.58) (Group II: Electro-thermo-debridement [ETD] + Moist wound treatment [MWT]) and US$ 25 (SE = 0.48) (Group III: MWT) in patients with a single chronic CL ulcer. From a societal perspective the budget impact analysis shows that the regimens' drug costs are lower than indirect disease cost. Average effectiveness in wound free days are 177 (SE = 0.36) in Group II, 147 (SE = 0.33) in Group III, and 129 (SE = 0.27) in Group I. The ICER of Group II versus Group I was US$ 0.09 and Group III versus Group I US$ 0.77, which is very cost-effective with a willingness-to-pay threshold of US$ 2 per wound free day. Within a Monte-Carlo probabilistic sensitivity analysis Group II was cost-effective in 80% of the cases starting at a willingness-to-pay of 80 cent per wound free day. CONCLUSIONS: Group II provided the most cost-effective treatment. The non-treatment alternative is not an option in the management of chronic CL ulcers. MWT of Group III should at least be practiced. The cost-effectiveness of Group III depends on the number of dressings necessary until complete wound closure.


Cost-Benefit Analysis , Leishmaniasis, Cutaneous , Models, Statistical , Wound Healing , Afghanistan/epidemiology , Antimony Sodium Gluconate/economics , Antimony Sodium Gluconate/therapeutic use , Antiprotozoal Agents/economics , Antiprotozoal Agents/therapeutic use , Debridement/economics , Decision Trees , Humans , Leishmaniasis, Cutaneous/economics , Leishmaniasis, Cutaneous/epidemiology , Leishmaniasis, Cutaneous/therapy , Monte Carlo Method , Randomized Controlled Trials as Topic , Ulcer/economics , Ulcer/epidemiology , Ulcer/therapy
4.
J Orthop Surg Res ; 10: 183, 2015 Dec 10.
Article En | MEDLINE | ID: mdl-26654318

BACKGROUND: Negative-pressure wound therapy is a technique to achieve wound healing in patients with non-healing wounds of the lower limb; vacuum-assisted closure (VAC) therapy is a technique to accelerate the healing of non-healing ulcers that fail to heal on their own (primary healing) (Plast Reconstr Surg 117:193-209S, 2006). Delayed wound healing or non-healing of ulcers is a significant health problem, particularly in older adults. The efficacy of VAC dressings has been demonstrated in several randomized controlled studies, which have shown significantly faster wound healing rates compared to conventional wound therapy (Lancet 366:1704-10, 2005; J Wound Care 17:426-32, 2008). However, commercially available VAC is costly. The aim of using custom made VAC was decided by our team due to lower socio-economic status of patients taken for study who could not have afforded charges of commercially available VAC unit. OBJECTIVE: Objective was to evaluate VAC therapy compared with conventional dressings in the treatment of non-healing lower limb ulcers in lower socio-economic patients. METHODS: Sixty patients of lower socio-economic status aged between 40 and 70 were prospectively studied for non-healing ulcers Wagner grade 2 or 3 and randomized into 2 groups. VAC dressing was kept for over a period of 2-7 weeks. Ulcers were treated until the wound closed spontaneously, surgically or until completion of the 50-day period, whichever was earlier. RESULTS: By seventh week, discharge disappeared in 96 % in VAC and only 54 % in conventional dressing group. Granulation tissue appeared in 100 % of patients in VAC group and only 63 % in conventional dressing group. The patients treated with VAC dressing in our study showed comparable wound reduction capabilities with an average wound size reduction of 56 % in comparison to conventional dressing group which had average wound size reduction of 29 %. Majority of wounds in VAC group got closed in 7 weeks. Patient satisfaction was excellent in the majority of patients in VAC group compared to those in conventional dressing group. CONCLUSION: The application of VAC™ had shown good results in our study.


Bandages/economics , Negative-Pressure Wound Therapy/economics , Ulcer/economics , Wound Healing , Adult , Aged , Bandages/standards , Case-Control Studies , Female , Humans , India , Lower Extremity/pathology , Male , Middle Aged , Negative-Pressure Wound Therapy/standards , Prospective Studies , Socioeconomic Factors , Treatment Outcome
5.
Aust Fam Physician ; 43(3): 143-6, 2014 Mar.
Article En | MEDLINE | ID: mdl-24600678

BACKGROUND: The management of wounds presents a significant burden to healthcare services, consuming a large amount of resources. This study aimed to determine the cost of wound care in general practice by conducting an audit of current wound management practices. METHODS: Eighteen general practices collected data on wound care episodes over a period of 14 days during December 2011. RESULTS: For most of the 332 wound care episodes, the total cost was greater than the total income, resulting in a net loss to the practice. General practitioner care was the greatest contributor to the total cost and the overwhelming majority of income was from Medicare Benefits Schedule billing items. DISCUSSION: In most cases, general practices are not recouping the costs of wound care. There is a need for policy makers and general practices to review wound care funding and practices to ensure equitable best practice care is being provided.


General Practice/economics , Health Care Costs , Wounds and Injuries/economics , Wounds and Injuries/therapy , Australia , Cross-Sectional Studies , Health Policy , Humans , Medical Audit , Ulcer/economics , Ulcer/nursing , Ulcer/therapy , Wounds and Injuries/etiology , Wounds and Injuries/nursing
7.
Sex Transm Infect ; 84(5): 400-4, 2008 Oct.
Article En | MEDLINE | ID: mdl-18426845

OBJECTIVE: To assess the cost-effectiveness of syndromic management for the treatment of sexually transmitted diseases (STD) in comparison with the strategies currently used in STD clinics in Taiwan. METHODS: Between July 2004 and June 2005, all male patients with genitourinary symptoms attending two hospitals were included in this study. Current clinical procedures (presumptive treatment and laboratory tests), aetiological diagnosis and syndromic management were compared in terms of diagnostic accuracy, treatment appropriateness, costs and effectiveness. RESULTS: 473 patients met the inclusion criteria and were enrolled in the study. 335 patients (71%) had urethral symptoms (discharge, dysuria or painful urination) and 138 (29%) had genital ulcers, sores and skin rashes. For the current approach, the sensitivity, specificity and positive predictive value (PPV) for the detection of chlamydial, gonococcal and combined forms of infection were 100%, 40.0% and 60.4%, respectively. In contrast, the sensitivity, specificity and PPV for the detection of syphilis were 100%, 86.7% and 70.2%, respectively. For syndromic management, the sensitivity, specificity and PPV detection of chlamydial, gonococcal and combined forms of infection were 85.0%, 40.0% and 56.4%, respectively. In contrast, the sensitivity, specificity and PPV for the detection of syphilis were 78.8%, 18.1% and 23.2%, respectively. The average cost of implementing a correct treatment using the current approach was US$54.27 and US$30.74 for urethritis and syphilis, respectively. For the aetiological approach, the average cost of implementing a correct treatment was US$32.83 and US$21.58 for urethritis and syphilis, respectively. For the syndromic approach, the average cost for a correct treatment was US$3.86 and US$14.30 for urethritis and syphilis, respectively. CONCLUSIONS: In this sample of patients attending STD clinics in Taiwan, syndromic management was found to be a more cost-effective protocol in terms of cost per treated STD patient compared with the current and aetiological protocols for STD.


Male Urogenital Diseases/therapy , Sexually Transmitted Diseases/therapy , Ulcer/therapy , Adolescent , Adult , Anti-Infective Agents/economics , Anti-Infective Agents/therapeutic use , Condoms/economics , Cost-Benefit Analysis , Health Education/economics , Humans , Male , Male Urogenital Diseases/economics , Middle Aged , Sexually Transmitted Diseases/economics , Taiwan , Ulcer/economics , Urethritis/economics , Urethritis/therapy
8.
Pharm World Sci ; 28(4): 194-8, 2006 Aug.
Article En | MEDLINE | ID: mdl-17066243

OBJECTIVES: To investigate if the reclassification of omeprazole from a prescription only medicine to pharmacy sale status had an impact on the prescribing and sales of ulcer-healing drugs and whether deprivation had any influence on this. SETTING: Primary care, Wales, UK. METHOD: Retrospective analysis (March 2002 to February 2005) of prescription data and pharmacy sales data. MAIN OUTCOME MEASURE: Number of items per 1,000 population. RESULTS: The number of prescription items for ulcer-healing drugs across Wales increased in each year of the study. The number of items per 1,000 population for proton pump inhibitors increased by 12.4% (473.3 to 531.8 items) in 2003/04 and 13.8% (531.8 to 605.1 items) in 2004/05, whereas the number of items per 1,000 population for H2 antagonists fell by 6.2% (149.1 to 139.9 items), and 5.7% (139.9 to 131.9 items) during 2003/04 and 2004/05, respectively. The sale of items per 1,000 population of H(2) antagonists increased by 34.3% (19.8 to 26.6 items) in 2003/04, but fell by 8.6% (26.6 to 24.3 items) in 2004/05. In February 2005, 12 months after reclassification, omeprazole accounted for 7.6% (2.0 items per 1,000 population) of the total sales (26.3 items per 1,000 population) of ulcer-healing drugs from pharmacies in Wales. Areas with high multiple deprivation and unemployment were significantly associated with the prescribing of ulcer-healing drugs, H2 antagonists and proton pump inhibitors. Multiple deprivation, unemployment and low income explained 21% of the variation in prescribing of ulcer-healing drugs. The sale of omeprazole through pharmacies was not related to these deprivation characteristics. CONCLUSION: Twelve months after the reclassification of omeprazole the market growth of H2 antagonists sold from pharmacies was halted although there was no apparent impact on the prescription of ulcer-healing drugs. As a consequence there was no saving to the health service drug budget associated with the reclassification of omeprazole.


Drug Prescriptions/statistics & numerical data , Omeprazole/therapeutic use , Ulcer/drug therapy , Anti-Ulcer Agents/classification , Anti-Ulcer Agents/therapeutic use , Drug Industry , Drug Prescriptions/economics , Drug Utilization Review/economics , Drug Utilization Review/statistics & numerical data , Health Services Needs and Demand , Histamine H2 Antagonists/economics , Histamine H2 Antagonists/therapeutic use , Humans , Marketing/economics , Marketing/statistics & numerical data , Nonprescription Drugs/economics , Omeprazole/classification , Primary Health Care/economics , Primary Health Care/statistics & numerical data , Proton Pump Inhibitors , Retrospective Studies , Tablets , Time Factors , Ulcer/economics , Unemployment , Wales
9.
Eksp Klin Gastroenterol ; (5): 79-82, 129, 2002.
Article Ru | MEDLINE | ID: mdl-12619585

Only in Saint Petersburg the application of omeprazole, hiconcil and fromilid in the treatment of adult patients with duodenal ulcer could save up to 26 million rubles per year due to the decrease in the number of recurrences. Yet these funds are still wasted with the persistence worthy of better application, since most general practitioners do not realize either economic or even clinical value of eradication. The above-mentioned calculations provide a ground for reflections on the improvement of methods of advanced training for specialists with the use of pharmacoepidemiological and pharmacoeconomic grounds for the selection of optimum remedies for the treatment of duodenal ulcer. A thorough clinical and economic evaluation of our actions, methods and preparations for treatment will make it possible to enhance the efficiency and quality of treatment, to avoid not only considerable undesirable drug reactions but also unjustified social costs in the way it is done in many countries.


Economics, Pharmaceutical , Ulcer/drug therapy , Ulcer/economics , Russia
10.
J Rheumatol ; 22(7): 1412-4, 1995 Jul.
Article En | MEDLINE | ID: mdl-7562787

Using misoprostol prophylaxis as an example, many of the methods employed in economic analyses that incorporate mathematical models were described. These included: decision analysis, cost effectiveness analysis (including incremental cost effectiveness analysis), one-way, multi-way, and probabilistic sensitivity analysis, and the estimation of quality adjusted life years for use in cost utility analysis. In the case of misoprostol prophylaxis, the cost effectiveness analysis demonstrated that, compared to the no prophylaxis alternative, prophylaxis cost an extra $650, on average, for every additional ulcer prevented, and was potentially cost saving for some high risk groups. The cost utility analysis demonstrated that prophylaxis resulted (on average) in modest additional costs and no additional quality of life benefits. Sensitivity analysis demonstrated that, at worst, prophylaxis reduced quality of life; at best, the incremental cost effectiveness ratio was $9333 for each quality adjusted life-year gained by prophylaxis compared to no prophylaxis. The results of the cost utility analysis also showed that prophylaxis may be cost saving in high risk groups, confirming the results of the cost effectiveness analysis. Finally, and perhaps most importantly, this analysis illustrated the importance of incorporating measures of health related quality of life into economic evaluation.


Misoprostol/therapeutic use , Outcome Assessment, Health Care/economics , Ulcer/prevention & control , Cost-Benefit Analysis , Humans , Misoprostol/adverse effects , Misoprostol/economics , Models, Econometric , Quality-Adjusted Life Years , Ulcer/economics
...